Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology and end results (SEER) data, 1973-1991
Davis F.G., Freels S., Grutsch J., et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology and end results (SEER) data, 1973-1991. J Neurosurg 88 (1998) 1-10
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 (1980) 1323-1329
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
Curran W.J., Scott C.B., Jorton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85 (1993) 704-710
Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype
Senger D., Cairncross J.G., and Forsyth P.A.J. Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype. Cancer J 9 (2003) 214-221
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study
Scott J.N., Rewcastle N.B., Brasher P.M.A., et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46 (1999) 183-188
Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen: Children's Cancer Group
Finlay J.L., Boyett J.M., Yates A.J., et al. Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen: Children's Cancer Group. J Clin Oncol 13 (1995) 112-123
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti A., Zhai G., Suzuki Y., et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22 (2004) 1926-1933
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas
Chakravarti A., Delaney M.A., Noll E., et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7 (2001) 2387-2395
Association of EGFR gene amplification and CDKN2 (p16/MTS) gene deletion in glioblastoma multiforme
Hayashi Y., Ueki K., Waha A., et al. Association of EGFR gene amplification and CDKN2 (p16/MTS) gene deletion in glioblastoma multiforme. Brain Pathol 7 (1997) 871-875
Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications
Hill C., Hunter S.B., and Brat D.J. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anatom Pathol 10 (2003) 212-217
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff I., Wang M., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2042
